Mangrove Partners Catalyst Pharmaceuticals, Inc. Transaction History

Mangrove Partners

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$2.97 - $3.83 $9 Million - $11.6 Million	-3,031,965 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$2.97 - $5.08 $291,743 - $499,008	-98,230 Reduced 3.14%	3,031,965 $9.01 Million
Q2 2020 Aug 14, 2020	SELL	$3.48 - $5.05 $4.26 Million - $6.19 Million	-1,225,221 Reduced 28.13%	3,130,195 $14.5 Million
Q1 2020 May 15, 2020	BUY	$2.61 - $5.21 $7.33 Million - $14.6 Million	2,807,100 Added 181.3%	4,355,416 $16.8 Million
Q4 2019 Feb 14, 2020	SELL	$3.67 - $5.7 $3.53 Million - $5.47 Million	-960,522 Reduced 38.29%	1,548,316 $5.81 Million
Q3 2019 Nov 14, 2019	SELL	$3.89 - $7.43 $5.17 Million - $9.87 Million	-1,328,343 Reduced 34.62%	2,508,838 $13.3 Million
Q2 2019 Aug 14, 2019	BUY	$2.7 - $6.11 $1.03 Million - $2.32 Million	380,140 Added 11.0%	3,837,181 $14.7 Million
Q1 2019 May 15, 2019	BUY	$2.11 - $5.33 $2.3 Million - $5.8 Million	1,088,711 Added 45.97%	3,457,041 $17.6 Million
Q4 2018 Feb 14, 2019	BUY	$1.92 - $3.62 $1.33 Million - $2.5 Million	690,386 Added 41.14%	2,368,330 $4.55 Million
Q2 2018 Aug 14, 2018	BUY	$2.26 - $3.84 $383,375 - $651,398	169,635 Added 11.25%	1,677,944 $5.24 Million
Q1 2018 May 15, 2018	BUY	$2.39 - $4.01 $1.39 Million - $2.34 Million	583,661 Added 63.12%	1,508,309 $3.61 Million
Q4 2017 Feb 14, 2018	BUY	$2.51 - $4.4 $2.32 Million - $4.07 Million	924,648	924,648 $3.62 Million

285

96.6M

29.2K

20.5K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.2B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.